Lil­ly diss­es Am­gen and Mi­rati as it de­buts new KRAS mol­e­cule

Eli Lil­ly is re­join­ing the KRAS hunt.

The In­di­anapo­lis Big Phar­ma re­vealed Thurs­day, in an ab­stract for AACR, that it has been work­ing on a new small mol­e­cule to tar­get the in­fa­mous onco­gene and are plan­ning to put it in­to Phase I lat­er this year. It marks Lil­ly’s first pub­lic for­ay in­to the field in near­ly a year, since it ditched its first mol­e­cule af­ter see­ing dan­ger­ous side ef­fects in five pa­tients.

The new ab­stract opens with a pub­lic diss. Like the old mol­e­cule, Lil­ly’s new can­di­date goes af­ter KRASG12C, the same mu­ta­tion that Am­gen and Mi­rati have tar­get­ed in their late-stage pro­grams. Those may be on a path to ap­proval but, Lil­ly said, they’re pret­ty weak drugs.

“Cur­rent­ly, there are no FDA-ap­proved KRAS-G12C in­hibitors,” the com­pa­ny’s re­searchers wrote, “and those in clin­i­cal de­vel­op­ment have rel­a­tive­ly mod­est ac­tiv­i­ty com­pared to oth­er ap­proved ther­a­pies tar­get­ing oth­er clas­sic onco­genic dri­vers.”

There are da­ta to bear the claim out: Al­though doc­tors and sci­en­tists have want­ed a KRAS drug for decades, on­ly about 30% to 40% of lung can­cer pa­tients with the mu­ta­tion re­spond to Am­gen and Mi­rati’s drugs and their tu­mors on­ly stop grow­ing for about 6 to 7 months.

That may help thou­sands of pa­tients in the next decade, but it falls short of the ef­fect seen in oth­er tar­get­ed lung can­cer drugs. The drug has hard­ly worked at all on oth­er tu­mor types.

Lil­ly’s sci­en­tists at­trib­uted the meh re­sponse seen in many pa­tients in part to mol­e­cules that don’t com­plete­ly fill the tar­get pock­et on KRASG12C. They claimed their drug was much bet­ter at do­ing so. It’s over 25 times more po­tent than Am­gen’s, they wrote: You need 3.35 nanomo­lars of the Lil­ly mol­e­cule to re­duce the pro­tein’s ac­tiv­i­ty by 50%, com­pared with 89.9 nanomo­lars of the Am­gen mol­e­cule. You need 47.9 nanomo­lars of Mi­rati’s mol­e­cule.

They will have the chance to prove that dif­fer­ence trans­lates in­to the clin­ic lat­er this year. The re­searchers not­ed, though, what Am­gen and Mi­rati’s clin­i­cal da­ta have al­ready borne out: Not every tu­mor is equal­ly de­pen­dent on KRAS and, for many, a com­bi­na­tion ap­proach might be nec­es­sary.

Bob Bradway, Amgen CEO (Scott Eisen/Bloomberg via Getty Images)

Am­gen bel­lies back up to the M&A ta­ble for an­oth­er biotech buy­out, this time with a $2.5B deal for an­ti­body play­er

Five months after Amgen CEO Bob Bradway stepped up to the M&A table and acquired Five Prime for $1.9 billion, following up with the smaller Rodeo acquisition, he’s gone back in for another biotech buyout.

This time around, Amgen is paying $900 million cash while committing up to $1.6 billion in milestones to bag the privately held Teneobio, an antibody drug developer which has expertise in developing new bispecifics and multispecifics. In addition, Amgen cited Teneobio’s “T-cell engager platform, which expands on Amgen’s existing leadership position in bispecific T-cell engagers by providing a differentiated, but complementary, approach to Amgen’s current BiTE platform.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.

How one start­up fore­told the neu­ro­science re­nais­sance af­ter '50 years of shit­show'

In the past couple of years, something curious has happened: Pharma and VC dollars started gushing into neuroscience research.

Biogen’s controversial new Alzheimer’s drug Aduhelm has been approved on the basis of removing amyloid plaque from the brain, but the new neuro-focused pharma and biotechs have much loftier aims. Significantly curbing or even curing the most notorious disorders would prove the Holy Grail for a complex system that has tied the world’s best drug developers in knots for decades.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ryan Watts, Denali CEO

De­nali slips as a snap­shot of ear­ly da­ta rais­es some trou­bling ques­tions on its pi­o­neer­ing blood-brain bar­ri­er neu­ro work

Denali Therapeutics had drummed up considerable hype for their blood-brain barrier technology since launching over six years ago, hype that’s only intensified in the last 14 months following the publications of a pair of papers last spring and proof of concept data earlier this year. On Sunday, the South San Francisco-based biotech gave the biopharma world the next look at in-human data for its lead candidate in Hunter syndrome.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.

Why is On­col­o­gy Drug De­vel­op­ment Re­search Late to the Dig­i­tal Bio­mark­ers Game?

During the recent Annual ASCO Meeting, thousands of cancer researchers and clinicians from across the globe joined together virtually to present and discuss the latest findings and breakthroughs in cancer research and care. There were more than 5000+ scientific abstracts presented during this event, yet only a handful involved the use of motion-tracking wearables to collect digital measures relating to activity, sleep, mobility, functional status, and/or quality of life. Although these results were a bit disappointing, they should come as no surprise to those of us in the wearable technology field.

Art Levinson (Calico)

Google-backed Cal­i­co dou­bles down on an­ti-ag­ing R&D pact with Ab­b­Vie as part­ners ante up $1B, start to de­tail drug tar­gets

Seven years after striking up a major R&D alliance, AbbVie and Google-backed anti-aging specialist Calico are doubling down on their work with a joint, $1 billion commitment to continuing their work together. And they’re also beginning to offer some details on where this project is taking them in the clinic.

According to their statement, each of the two players is putting up $500 million more to keep the labs humming.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Pan­el of neu­ro­science ex­perts lays out the com­pli­ca­tions with us­ing Bio­gen's new Alzheimer's drug

Treatment of early Alzheimer’s patients with Biogen’s new drug Aduhelm should closely resemble how the drug was studied in its pivotal clinical trials, according to new recommendations from a panel of neuroscience experts led by UNLV’s Jeffrey Cummings.

“Those considering aducanumab therapy should understand that the expected benefit is slowing of cognitive and functional decline; improvement of the current clinical state is not anticipated,” they wrote Tuesday in The Journal of Prevention of Alzheimer’s Disease, noting that some of their recommendations are more specific or more restrictive than the information provided in the FDA’s prescribing information.

Busi­ness­es and schools can man­date the use of Covid-19 vac­cines un­der EUAs, DOJ says

As public and private companies stare down the reality of the Delta variant, many are now requiring that their employees or students be vaccinated against Covid-19 prior to attending school or to returning or starting a new job. Claims that such mandates are illegal or cannot be used for vaccines under emergency use authorizations have now been dismissed.

Setting the record straight, the Department of Justice on Monday called the mandates legal in a new memo, even when used for people with vaccines that remain subject to EUAs.

Ugur Sahin, BioNTech CEO (Bernd von Jutrczenka/dpa via AP Images)

BioN­Tech is spear­head­ing an mR­NA vac­cine de­vel­op­ment pro­gram for malar­ia, with a tech trans­fer planned for Africa

Flush with the success of its mRNA Covid-19 vaccine, BioNTech is now gearing up for one of the biggest challenges in vaccine development — which comes without potential profit.

The German mRNA pioneer says it plans to work on a jab for malaria, then transfer the tech to the African continent, where it will work with partners on developing the manufacturing ops needed to make this and other vaccines.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.

J&J’s Rem­i­cade — the poster child for how to block biosim­i­lars — fi­nal­ly set­tles Pfiz­er suit

Biosimilars have proven time and again (although mostly in Europe) that competition works to bring down the cost of a once-pricey biologic, and can even expand its use.

J&J’s Remicade, however, has always proven to be an outlier.

Back in 2016, Pfizer won FDA approval for its infliximab biosimilar, known as Inflectra, but when the launch foundered, the company sued J&J, claiming that the company’s plan to block biosimilar competition worked incredibly well. Pfizer even went on to win FDA approval for a second infliximab biosimilar in 2017, known as Ixifi, but decided to never launch it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.